Therapeutic Alliances for Optimizing the Management of Patients with Prostate Cancer: SOGUG Multidisciplinary Expert Panel Recommendations. Volumen 17, Issue 19. 1 October 2025.
Pilot phase 2 study of the efficacy, safety, and tolerability of first-line cabozantinib for older fragile patients with metastatic renal cell carcinoma: The SOGUG-CABOMAYOR study. Journal of Geriatric Oncology. Volume 16, Issue 8, November 2025, 102340.
Effectiveness and Safety of Cabozantinib Treatment in Patients with Advanced Renal Cell Carcinoma in Spanish and Portuguese Real-world Practice: The SOGUG-SPRWEC Study. Clinical Genitourinary Cancer. Volume 23, Issue 5, October 2025, 102402
SEOM – SOGUG clinical guideline for urothelial cancer. September 2025
Split-Dose Cisplatin Plus Atezolizumab for Patients With Urothelial Carcinoma Who Are Considered Ineligible for Full Doses of Cisplatin (SOGUG-AUREA). JCO. 31 July 2025.
Real‑world data on avelumab in first‑line maintenance therapy for advanced or metastatic urothelial carcinoma: the SOGUG‑AVELUMAB RWD study. Clinical and Translational Oncology. Volume 27, Issue 7. 09 July 2025
Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial. Clinical Cancer Research. Volume 31, Issue 9. 1 May 2025.
Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial. 15 February, 2025.
Nacional
Internacional
Nuestros patrocinadores
